300 related articles for article (PubMed ID: 29336269)
21. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors.
Leonetti F; Favia A; Rao A; Aliano R; Paluszcak A; Hartmann RW; Carotti A
J Med Chem; 2004 Dec; 47(27):6792-803. PubMed ID: 15615528
[TBL] [Abstract][Full Text] [Related]
22. Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch.
Ratre P; Mishra K; Dubey A; Vyas A; Jain A; Thareja S
Anticancer Agents Med Chem; 2020; 20(17):1994-2004. PubMed ID: 32593281
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and molecular docking of N,N'-disubstituted thiourea derivatives as novel aromatase inhibitors.
Pingaew R; Prachayasittikul V; Anuwongcharoen N; Prachayasittikul S; Ruchirawat S; Prachayasittikul V
Bioorg Chem; 2018 Sep; 79():171-178. PubMed ID: 29758407
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, in vitro and in silico studies of some novel thiazole-dihydrofuran derivatives as aromatase inhibitors.
Osmaniye D; Görgülü Ş; Sağlık BN; Levent S; Özkay Y; Kaplancıklı ZA
Bioorg Chem; 2021 Sep; 114():105123. PubMed ID: 34214753
[TBL] [Abstract][Full Text] [Related]
25. An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors.
Neves MA; Dinis TC; Colombo G; Sá e Melo ML
Eur J Med Chem; 2009 Oct; 44(10):4121-7. PubMed ID: 19500885
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, biological evaluation, and docking study of indole aryl sulfonamides as aromatase inhibitors.
Fantacuzzi M; De Filippis B; Gallorini M; Ammazzalorso A; Giampietro L; Maccallini C; Aturki Z; Donati E; Ibrahim RS; Shawky E; Cataldi A; Amoroso R
Eur J Med Chem; 2020 Jan; 185():111815. PubMed ID: 31732252
[TBL] [Abstract][Full Text] [Related]
27. Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study.
Adhikari N; Amin SA; Saha A; Jha T
Eur J Med Chem; 2017 Sep; 137():365-438. PubMed ID: 28622580
[TBL] [Abstract][Full Text] [Related]
28. Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans.
Trösken ER; Scholz K; Lutz RW; Völkel W; Zarn JA; Lutz WK
Endocr Res; 2004 Aug; 30(3):387-94. PubMed ID: 15554355
[TBL] [Abstract][Full Text] [Related]
29. Aromatase inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and molecular modeling studies of novel phenothiazine derivatives carrying sulfonamide moiety as hybrid molecules.
Ghorab MM; Alsaid MS; Samir N; Abdel-Latif GA; Soliman AM; Ragab FA; Abou El Ella DA
Eur J Med Chem; 2017 Jul; 134():304-315. PubMed ID: 28427017
[TBL] [Abstract][Full Text] [Related]
30. Aromatase inhibition by 2-methyl indole hydrazone derivatives evaluated via molecular docking and in vitro activity studies.
Ozcan-Sezer S; Ince E; Akdemir A; Ceylan ÖÖ; Suzen S; Gurer-Orhan H
Xenobiotica; 2019 May; 49(5):549-556. PubMed ID: 29804490
[TBL] [Abstract][Full Text] [Related]
31. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
32.
Shah U; Patel S; Patel M; Jain N; Pandey N; Chauhan A; Patel A; Patel S
Anticancer Agents Med Chem; 2022; 22(7):1370-1385. PubMed ID: 34455966
[TBL] [Abstract][Full Text] [Related]
33. Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives.
Bonfield K; Amato E; Bankemper T; Agard H; Steller J; Keeler JM; Roy D; McCallum A; Paula S; Ma L
Bioorg Med Chem; 2012 Apr; 20(8):2603-13. PubMed ID: 22444875
[TBL] [Abstract][Full Text] [Related]
34. New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.
Stauffer F; Furet P; Floersheimer A; Lang M
Bioorg Med Chem Lett; 2012 Mar; 22(5):1860-3. PubMed ID: 22335894
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and characterization of azole isoflavone inhibitors of aromatase.
Hackett JC; Kim YW; Su B; Brueggemeier RW
Bioorg Med Chem; 2005 Jun; 13(12):4063-70. PubMed ID: 15911319
[TBL] [Abstract][Full Text] [Related]
36. Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.
Su B; Chen S
Bioorg Med Chem Lett; 2009 Dec; 19(23):6733-5. PubMed ID: 19854050
[TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibitors in the treatment of breast cancer.
Brueggemeier RW; Hackett JC; Diaz-Cruz ES
Endocr Rev; 2005 May; 26(3):331-45. PubMed ID: 15814851
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, Aromatase Inhibitory, Antiproliferative and Molecular Modeling Studies of Functionally Diverse D-Ring Pregnenolone Pyrazoles.
Banday AH; Saeed BA; Al-Masoudi NA
Anticancer Agents Med Chem; 2021; 21(13):1671-1679. PubMed ID: 33238853
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, biological evaluation, and molecular docking studies of new pyrazol-3-one derivatives with aromatase inhibition activities.
Yi XJ; El-Idreesy TT; Eldebss TM; Farag AM; Abdulla MM; Hassan SA; Mabkhot YN
Chem Biol Drug Des; 2016 Dec; 88(6):832-843. PubMed ID: 27565954
[TBL] [Abstract][Full Text] [Related]
40. In Silico Molecular Interaction Studies of Chitosan Polymer with Aromatase Inhibitor: Leads to Letrozole Nanoparticles for the Treatment of Breast Cancer.
Mishra K; Verma SK; Ratre P; Banjare L; Jain A; Thareja S; Jain AK
Anticancer Agents Med Chem; 2021; 21(9):1191-1199. PubMed ID: 32842946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
